PUBLICATIONS：

1. Huang HC, Hsu SJ, Chang CC, Chuang CL, Hou MC, Lee FY. Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats. Int J Mol Sci. 2022 Jul 2;23(13):7378. IF=5.924 (Biochemistry, molecular biology; R/C=67/295, 23%)通訊作者
2. Hsu SJ, Huang HC, Chuang CL, Chang CC, Hou MC, Lee FY, Lee SD. Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats. Pharmaceutics. 2020 Apr 2;12(4):E320. IF=6.321 (Pharmacology and pharmacy, R/C 26/267, 11%)通訊作者
3. Chang T, Ho HL, Hsu SJ, Chang CC, Tsai MH, Huo TI, Huang HC, Lee FY, Hou MC, Lee SD. Glucobrassicin Metabolites Ameliorate the Development of Portal Hypertension and Cirrhosis in Bile Duct-Ligated Rats. Int J Mol Sci. 2019 Aug 26;20(17). IF=5.924 (Biochemistry, molecular biology; R/C=67/295, 23%) 通訊作者
4. Chang CC, Chuang CL, Tsai MH, Hsin IF, Hsu SJ, Huang HC, Lee FY, Lee SD. Effects of Caffeine Treatment on Hepatopulmonary Syndrome in Biliary Cirrhotic Rats. Int J Mol Sci. 2019 Mar 28;20(7). IF=5.924 (Biochemistry, molecular biology; R/C=67/295, 23%) 第一作者
5. Wu KC, Huang HC, Chang T, Lee WS, Chuang CL, Hsin IF, Hsu SJ, Lee FY, Chang CC, Lee SD.Effect of sirolimus on liver cirrhosis and hepatic encephalopathy of common bile duct-ligated rats. Eur J Pharmacol. 2018 Apr 5;824:133-139. IF=4.432 (Pharmocology and Pharmacy, Research & Experiment; R/C=86/276, 31%)通訊作者